The European Commission is “monitoring developments” in the tracker mortgage overcharging issue in Ireland but is not yet in a position to open an investigation.
Maria Velentza, director of the Competition Directorate-General of the Commission, said it is following the Central Bank’s examination of the mortgage market. Ms Velentza was responding to a complaint alleging collusion by the Irish banks in overcharging customers by Fine Gael MEP Brian Hayes. Mr Hayes complained that the banks were acting “as a cartel to restrict competition by controlling mortgage rates and sharing the Irish mortgage market.”
Ms Velentza said the Commission took these views “very seriously” but that, in the event any evidence could be provided of anti-competitive behavior, it would be the Competition and Consumer Protection Commission (CCPC) which would investigate at first instance.
“We do not currently have any information, neither from the Central Bank’s investigation nor from other sources, which would indicate that Irish banks actively colluded in this matter. If you have more detailed information in this respect we would invite you submitting it directly to the Irish Competition and Consumer Protection Commission,” she said.
Full Content: Irish Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan